Skip to search formSkip to main contentSkip to account menu

tumor necrosis factor-alpha, CNGRC fusion protein, human

Known as: CNGRC peptide-TNF alpha conjugate, NGR-hTNF, NGR-TNF, human 
A cytokine-peptide conjugate composed of the cytokine tumor necrosis factor alpha (TNF-alpha) chemically linked to the peptide CNGRC. The peptide… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent Terminology

Broader (2)

Recombinant Fusion ProteinsTumor Necrosis Factor-alpha

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Tumor vascular infarction: prospects and challenges
Induction of thrombosis in tumor vasculature represents an appealing strategy for combating cancer. Formation of fibrin clots may… 
Highly Cited
2015
Highly Cited
2015
Dual-modified liposomes with a two-photon-sensitive cell penetrating peptide and NGR ligand for siRNA targeting delivery.
2013
2013
Oxidation-induced Structural Changes of Ceruloplasmin Foster NGR Motif Deamidation That Promotes Integrin Binding and Signaling
Background: Asparagine deamidation at Asn-Gly-Arg (NGR) sites leads to the isoAsp-Gly-Arg (isoDGR) integrin-binding motif… 
2012
2012
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
Background:The NGR-hTNF (asparagine–glycine–arginine–human tumour necrosis factor) is able to promote antitumour immune responses… 
Highly Cited
2011
Highly Cited
2011
Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes
Background Single-walled carbon nanotubes (SWNT) are poorly soluble in water, so their applications are limited. Therefore… 
Highly Cited
2011
Highly Cited
2011
Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
Purpose: NGR-hTNF exploits the tumor-homing peptide asparagine-glycine-arginine (NGR) for selectively targeting TNF-α to an… 
Highly Cited
2010
Highly Cited
2010
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
PURPOSE NGR-hTNF consists of human tumor necrosis factor alpha (hTNF-alpha) fused to the tumor-homing peptide asparagine-glycine… 
Highly Cited
2010
Highly Cited
2010
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
2010
2010
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
Highly Cited
2009
Highly Cited
2009
[Expression of omentin in adipose tissues in obese and type 2 diabetic patients].
OBJECTIVE To analyze the mRNA expression of omentin mRNA level in subcutaneous and omental adipose tissues of normal, obese, and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)